Wellesley, MA (PRWEB) May 28, 2013
The global central nervous system (CNS) biomarker market was valued at nearly $2 billion in 2012. The market is projected to reach nearly $5.1 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 20.7%. This aggressive growth rate is driven by several factors, including the increase in public-private partnerships with government support, pressure to keep healthcare costs down, an increasing elderly population, and the rapid advancement of genomic and proteomic technologies, which have impacted the CNS biomarker diagnostics area.
The CNS biomarker discovery, drug development, and molecular diagnostics segments represent 15.1% (nearly $2 billion) of the total biomarker market, valued at $13.2 billion in 2012. The global market for all biomarkers is projected to grow to more than $32.1 billion by 2017, and the CNS biomarker segment is expected to reach $5.1 billion, increasing its market share to 16.1% of the total market for biomarkers.
The projected growth of CNS biomarkers revenue is based on the projection that a number of CNS biomarkers in the early stages of development will successfully complete their testing and validation and achieve FDA approval during the forecast period of 2012 to 2017.
The CNS molecular diagnostic market is expected to see the greatest growth, increasing from $196 million in 2012 to nearly $1.5 billion by 2017 at a CAGR of 49.6%. This large increase is due to the number of diagnostic tests that are in company pipelines. Tests for Alzheimer’s disease, schizophrenia, and multiple sclerosis are expected to be commercialized within the next few years. These disorders represent large markets and have unmet needs in both diagnosis and treatment.
Growth within the CNS biomarker market for drug development has been modest in the years prior to 2012. As more validated biomarkers become available for patient segmentation and assessment of efficacy for clinical trials, this market will begin to exhibit significant growth during the five-year forecast period. Revenues from this segment in 2012 are projected at $194 million and are expected to increase to $776 million by 2017, a CAGR of 32%.
The discovery segment of the CNS biomarker market will exhibit modest growth during the next five years, in part because many of the proteins involved in the major CNS disease pathways have been discovered. New discoveries are likely in the future, however, as proteomics research advances. Projected revenues for CNS biomarker discovery in 2012 were nearly $1.6 billion, and this is expected to increase to nearly $2.9 billion by the end of 2017 at a CAGR of 12.3%.
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets (BIO074B) will help its readers:
- Assess the various technologies used for CNS biomarker discovery and future diagnostics
- Understand the process of CNS biomarker development from discovery to commercialization and the path toward adoption
- Examine the regulatory landscape and government’s role
- Examine the future advances that need to be made in the diagnosis and treatment of various CNS disorders
- Determine current and future CNS biomarker markets.